CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright ...

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG ...

In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price ...

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 ...

The average of price targets set by Wall Street analysts indicates a potential upside of 157.9% in CG Oncology, Inc. (CGON). While the effectiveness of this highly sought-after metric is questionable, ...

EDT CG Oncology (CGON) files automatic mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and ...

CG Oncology, Inc. (CGON) closed the last trading session at $26.42, gaining 2.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

(MENAFN- GlobeNewsWire - Nasdaq) - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive ...

CG Oncology, Inc. ( ($CGON) ) has released its Q4 earnings. Here is a breakdown of the information CG Oncology, Inc. presented to its investors.

- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated ...